| |
 |
PREFACE [Hot Topic: Novel Cancer-Targeting Agents/Application Strategies Developed from MMP Science]
 |
| |
|
pp.687-687 (1) Author: Isao Okazaki |
| |
|
|
| |
|
Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
|
| |
|
pp.688-706 (19) Authors: Isao Okazaki, Kazuki Nabeshima |
| |
|
|
| |
|
Inhibiting Matrix Metalloproteinases, an Old Story with New Potentials for Cancer Treatment
|
| |
|
pp.707-717 (11) Authors: Dimitris Stellas, Evangelia Patsavoudi |
| |
|
|
| |
|
RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
|
| |
|
pp.718-725 (8) Author: Siddavaram Nagini |
| |
|
|
| |
|
Modulation of MMPs by Cell Surface Integrin Receptor α5β1
|
| |
|
pp.726-732 (7) Authors: Sekhar Pal, Kirat Kumar Ganguly, Shuvojit Moulik, Amitava Chatterjee |
| |
|
|
| |
|
MicroRNAs in Cancer: Small Molecules, Big Chances
|
| |
|
pp.733-743 (11) Authors: Frank Antonicelli, David Vallerand, Aurelie Allgayer, Trussardi-Regnier, Florent Grange, William Hornebeck and Philippe Bernard |
| |
|
|
| |
|
Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
|
| |
|
pp.744-752 (9) Authors: Yasuhiro Hida, Jun-ichi Hamada |
| |
|
|
| |
|
Novel Strategies for Hepatocellular Carcinoma Based on MMPs Science
|
| |
|
pp.753-763 (11) Authors: Isao Okazaki, Yutaka Inagaki |
| |
|
|
| |
|
MMPs in Ovarian Cancer as Therapeutic Targets
|
| |
|
pp.764-772 (9) Authors: Amer Karam, Oliver Dorigo |
| |
|
|
| |
|
Regulation of MMPs During Melanoma Progression: From Genetic to Epigenetic
|
| |
|
pp.773-782 (10) Authors: Antonicelli Frank, Vallerand David, Trussardi-Regnier Aurelie, Grange Florent, Hornebeck William, Bernard Philippe |
| |
|
|
| |
|
The Cytotoxic Effect of Emetine and CGP-74514A Studied with the Hollow Fiber Model and ArrayScan Assay in Neuroendocrine Tumors In Vitro
|
| |
|
pp.783-790 (8) Authors: Dhana E. Larsson, Saadia B. Hassan, Kjell Oberg, Dan Granberg |
| |
|
|
| |
|
A Novel Fusicoccin Derivative Preferentially Targets Hypoxic Tumor Cells and Inhibits Tumor Growth in Xenografts
|
| |
|
pp.791-800 (10) Authors: Koshi Kawakami, Miho Hattori, Takatsugu Inoue, Yuriko Maruyama, Junko Ohkanda, Nobuo Kato, Miki Tongu, Takaya Yamada, Miho Akimoto, Keizo Takenaga, Takeshi Sassa, Junji Suzumiy, Yoshio Honma |
| |
|
|
| |
|
Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition
|
| |
|
pp.801-806 (6) Authors: Jean M. Brunel, Chanaz Salmi-Smail, Audrey Restouin, Thomas Prebet, Norbert Vey, Yves Collette |
| |
|
|
| |
|
Calculation of Molecular Features with Apparent Impact on Both Activity of Mutagens and Activity of Anticancer Agents
|
| |
|
pp.807-817 (11) Authors: Andrey A. Toropov, Alla P. Toropova, Emilio Benfenati, Giuseppina Gini, Danuta Leszczynska, Jerzy Leszczynski |
| |
|
|
| |
|
Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
|
| |
|
pp.818-828 (11) Authors: Zhisong Cao, John Mendoza, Anthony Kozielski, Xing Liu, Albert DeJesus, Yang Wang, Chang-Guo Zhan, Dana Vardeman, Beppino Giovanella |
| |
|
|
